# Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

> **NCT00793845** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** Thiotepa
- **DRUG:** Melphalan
- **RADIATION:** Total body irradiation

## Key facts

- **NCT ID:** NCT00793845
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2015-01
- **Final completion:** 2018-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793845, "Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00793845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*